TY - JOUR
T1 - Impact of neoadjuvant chemotherapy with FOLFOX/FOLFIRI on disease-free and overall survival of patients with colorectal metastases
AU - Boostrom, Sarah Y.
AU - Nagorney, David M.
AU - Donohue, John H.
AU - Harmsen, Scott
AU - Thomsen, Kristine
AU - Que, Florencia
AU - Kendrick, Michael
AU - Reid-Lombardo, Kaye M.
N1 - Funding Information:
Acknowledgement Dr. Reid-Lombardo was supported by Grant Number 1 UL1 RR024150 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), and the NIH Roadmap for Medical Research. Its contents are solely the responsibility of the authors and do not necessarily represent the official view of NCRR or NIH. Information on NCRR is available at http://www.ncrr.nih.gov/. Information on Reengineering the Clinical Research Enterprise can be obtained from http:// nihroadmap.nih.gov.
PY - 2009
Y1 - 2009
N2 - Study Aims To determine if neoadjuvant FOLFOX/FOLFIRI is associated with improved disease-free survival (DFS) or overall survival (OS) in patients with colorectal metastases (CRM) to the liver. Methods Ninety-nine patients (from 457 eligible) with CRM that underwent hepatic resection during 2000 to 2005 were included. Group 1 (n=44) patients received neoadjuvant FOLFOX/FOLFIRI, and Group 2 (n=55) did not receive neoadjuvant therapy. Results There were 58% men. The median age for Group 1 was 58 and Group 2, 64 (p=0.03). OS for Group 1 at 1, 3, and 5 years was 93%, 62%, and 51%, respectively, with a median OS of 5.8 years. In Group 2 survival at 1l, 3, and 5 years was 90%,63%, and 45%, respectively, with a median OS of 3.7 years (HR 1.06, p=0.87). The DFS for Group 1 at 1, 3, and 5 years was 51%, 20%, and 20%, with a median DFS of 1.1 years and Group 2 at 1, 3, and 5 years was 58%, 32%, and 32% (median DFS-1.2 years; HR=1.24, p=0.45). Conclusions Neoadjuvant FOLFOX/FOLFIRI was employed more frequently in younger patients with CRM; however, neoadjuvant chemotherapy for CRM was not significantly associated with an increase in OS or DFS, despite additional adjuvant therapy.
AB - Study Aims To determine if neoadjuvant FOLFOX/FOLFIRI is associated with improved disease-free survival (DFS) or overall survival (OS) in patients with colorectal metastases (CRM) to the liver. Methods Ninety-nine patients (from 457 eligible) with CRM that underwent hepatic resection during 2000 to 2005 were included. Group 1 (n=44) patients received neoadjuvant FOLFOX/FOLFIRI, and Group 2 (n=55) did not receive neoadjuvant therapy. Results There were 58% men. The median age for Group 1 was 58 and Group 2, 64 (p=0.03). OS for Group 1 at 1, 3, and 5 years was 93%, 62%, and 51%, respectively, with a median OS of 5.8 years. In Group 2 survival at 1l, 3, and 5 years was 90%,63%, and 45%, respectively, with a median OS of 3.7 years (HR 1.06, p=0.87). The DFS for Group 1 at 1, 3, and 5 years was 51%, 20%, and 20%, with a median DFS of 1.1 years and Group 2 at 1, 3, and 5 years was 58%, 32%, and 32% (median DFS-1.2 years; HR=1.24, p=0.45). Conclusions Neoadjuvant FOLFOX/FOLFIRI was employed more frequently in younger patients with CRM; however, neoadjuvant chemotherapy for CRM was not significantly associated with an increase in OS or DFS, despite additional adjuvant therapy.
KW - Neoadjuvant therapy. FOLFOX. Hepatectomy. Colorectal cancer metastases. Survival
UR - http://www.scopus.com/inward/record.url?scp=77952993629&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77952993629&partnerID=8YFLogxK
U2 - 10.1007/s11605-009-1007-3
DO - 10.1007/s11605-009-1007-3
M3 - Article
C2 - 19760306
AN - SCOPUS:77952993629
SN - 1091-255X
VL - 13
SP - 2003
EP - 2010
JO - Journal of Gastrointestinal Surgery
JF - Journal of Gastrointestinal Surgery
IS - 11
ER -